Compare Incyte Corporation (INCY) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Macy's Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Macy's Inc trades at $23.75 (market cap $6.13B). The key difference: Incyte Corporation is far larger — about 3.8× Macy's Inc's market cap, and Macy's Inc pays a 3.29% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | M | |
|---|---|---|
Market Cap | $23.11B | $6.13B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $25.96 |
52-Week Low | $67.38 | $11.90 |
Enterprise Value | $19.13B | $9.95B |
Dividend Yield | — | 3.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Macy's (M) trades at $23.80, up 0.51% today, with a bullish technical signal and strong recent earnings beats. The stock shows improving fundamentals with a 2.94% net margin and attractive valuation at a P/E of 9.63. Recent news highlights a successful turnaround under the 'Bold New Chapter' strategy, including same-store sales growth and digital innovation initiatives.
Outlook remains positive with analyst consensus target at $24.83, though risks include margin pressure and retail competition. The stock offers value with upside potential from operational improvements, supported by Berkshire Hathaway's recent 3 million share purchase disclosed in Q1 2026 (13F filing May 15, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
